亚宝药业
(600351)
| 流通市值：49.00亿 | | | 总市值：49.00亿 |
| 流通股本：7.00亿 | | | 总股本：7.00亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,139,408,464.81 | 614,533,394.31 | 2,686,037,568.67 | 2,121,509,818.79 |
| 营业收入 | 1,139,408,464.81 | 614,533,394.31 | 2,686,037,568.67 | 2,121,509,818.79 |
| 二、营业总成本 | 944,321,678.49 | 490,742,317.93 | 2,391,542,009.25 | 1,854,942,934.53 |
| 营业成本 | 540,585,784.67 | 289,256,463.32 | 1,297,853,138.07 | 1,023,628,071.91 |
| 税金及附加 | 17,290,947.31 | 8,831,932.81 | 34,045,339.09 | 26,570,623.72 |
| 销售费用 | 222,145,153.68 | 111,914,490.55 | 661,866,911.31 | 514,819,616.99 |
| 管理费用 | 116,732,896.12 | 59,383,276.34 | 259,067,167.24 | 200,458,781.73 |
| 研发费用 | 48,536,984.41 | 21,567,036.65 | 139,523,419.89 | 89,911,769.62 |
| 财务费用 | -970,087.7 | -210,881.74 | -813,966.35 | -445,929.44 |
| 其中:利息费用 | 1,205,793.04 | 644,477.45 | 5,347,631.23 | 4,660,671.71 |
| 其中:利息收入 | 2,347,848.85 | 892,131.73 | 6,448,673.81 | 5,310,753.39 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 419,744.99 | 452,808.9 | -2,847,479.62 | 104,653.02 |
| 加:投资收益 | 992,783.8 | 603,719.9 | -188,368.93 | 82,208.83 |
| 资产处置收益 | 50,194.26 | 26,605.32 | 347,086.9 | 175,751.27 |
| 资产减值损失(新) | -10,010,853.29 | -3,095,784.05 | -42,162,919.81 | -6,806,022.31 |
| 信用减值损失(新) | 7,487,536.47 | -2,783,962.95 | 4,875,175.46 | 1,362,672.84 |
| 其他收益 | 17,991,574.96 | 9,327,516.84 | 45,434,066.6 | 26,887,624.07 |
| 四、营业利润 | 212,017,767.51 | 128,321,980.34 | 299,953,120.02 | 288,373,771.98 |
| 加:营业外收入 | 1,141,454.1 | 616,576.88 | 1,634,646.67 | 1,158,966.09 |
| 减:营业外支出 | 729,081.77 | 633,172.16 | 9,479,638.95 | 5,521,404.09 |
| 五、利润总额 | 212,430,139.84 | 128,305,385.06 | 292,108,127.74 | 284,011,333.98 |
| 减:所得税费用 | 37,241,723.11 | 22,236,917.2 | 68,192,627.05 | 55,543,479.47 |
| 六、净利润 | 175,188,416.73 | 106,068,467.86 | 223,915,500.69 | 228,467,854.51 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 175,188,416.73 | 106,068,467.86 | 223,915,500.69 | 228,467,854.51 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 174,397,240.67 | 107,269,233.54 | 242,688,462.41 | 234,933,135.46 |
| 少数股东损益 | 791,176.06 | -1,200,765.68 | -18,772,961.72 | -6,465,280.95 |
| 扣除非经常损益后的净利润 | 159,681,557.75 | 100,877,438.17 | 215,457,408.25 | 217,041,072.59 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.25 | 0.15 | 0.34 | 0.32 |
| 八、其他综合收益 | - | - | -1,288,990.13 | - |
| 归属于母公司股东的其他综合收益 | - | - | -1,288,990.13 | - |
| 九、综合收益总额 | 175,188,416.73 | 106,068,467.86 | 222,626,510.56 | 228,467,854.51 |
| 归属于母公司股东的综合收益总额 | 174,397,240.67 | 107,269,233.54 | 241,399,472.28 | 234,933,135.46 |
| 归属于少数股东的综合收益总额 | 791,176.06 | -1,200,765.68 | -18,772,961.72 | -6,465,280.95 |
| 公告日期 | 2025-08-16 | 2025-04-26 | 2025-04-26 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |